Wire · opportunities
FDA Grants Fast Track Designation to BH-30643 in EGFR C797S+ NSCLC
◆ Sectors
Biotech
◆ Geography
United States
◆ Source
◆ Verified
Fusion42 · 18 August 2026 · Fusion42 review
The FDA has granted Fast Track designation to BH-30643, a drug candidate targeting EGFR C797S mutation-positive non-small cell lung cancer (NSCLC), expediting its development and review process in the United States.
This Wire brief sits within Fusion42's coverage of Biotech, and 2 sources have reported it.
◆ ◆ The Wire takeaway
You have a faster path to US market for EGFR-resistant NSCLC treatments with this new FDA Fast Track. Accelerate your clinical plans or partnerships now to take advantage of shortened regulatory timelines.
◆ Coverage
2 sources · 18 Aug 2026
◆ Related on Wire
◆ Topics
Biotechfdafast-trackoncologydrug-developmentnsclcegfr